What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Health & MedicineOne-Off11mndManifold MarketsGeen KYCGeverifieerde afwikkelingsgegevensRedelijk gekalibreerdHuidige gemeenschapsvoorspelling60-69% 25.6%Koploper van 7 uitkomsten
Voorspellers
14
Vraagtype
multiple choice
Methodologie
Play-money forecasting platform
Brontype
Voorspelling
7d wijziging
-2.3 pts
Marktdata
Bijgewerkt 18 uur geleden
Verouderd15 mrt 24, 21:29 UTC2 sep 27, 06:59 UTC
Trends
Gerelateerde Markten
Gerelateerde vragen voor context, geen vergelijking van gelijkwaardige contracten.
Will the VLA15 Lyme Disease vaccine "pass" its phase 3 human trial?
Manifold MarketsWill FDA approve any mRNA vaccine against malaria before 2028?
Manifold MarketsWill BioAge's BGE-102 achieve its primary endpoint in the Phase 2 QUELL-CV trial before January 1, 2028?
Manifold MarketsSkin cancer vaccine BLA submitted by which date?
PolymarketTdi-11861 (a fast-acting male contraceptive) approved for human clinical trials by the end of 2026?
FutuurFDA approves skin cancer vaccine by which date?
PolymarketRegels
The 12 month phase 3 data indicates 75% vaccine efficacy of R21 in annual malaria sites in children at 12 months after the first dose was delivered.
- Phase 2b data at a 42 month timepoint showed 71% efficacy after four total doses (Abstract here, #6949).
- Resolves upon publication of peer-reviewed data from the R21 team at Oxford (expected to be before September 1st, 2026).
- Vaccine efficacy is defined as the primary endpoint for time to clinical malaria in seasonal sites, as defined in the paper linked above.
- 1Day Sooner has an R21 Status Report available here that may be useful.
- More malaria-related questions can be found on our Manifold account here.
Open markten
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Totaal volume
- € 15,6 mln.
- 24u volume
- € 18,3K
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Totaal volume
- € 1,6 mln.
- 24u volume
- € 5,2K
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before October+64.0pt98%
- before 2027+22.0pt98%
- before December+30.0pt98%
+3 extra uitkomsten
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt65%
- September+2.0pt41%
- June28%
- Totaal volume
POLYMARKETNew pandemic in 2026?
- No+0.5pt94%
- Yes-0.5pt6%
- Totaal volume
- € 916K
- 24u volume
- € 1,5K
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-2.0pt57%
+2 extra uitkomsten
- Totaal volume
- € 863,6K
- 24u volume
- € 1K
- Ebola pandemic in 2026?
- Will 3 mg THC beverages be federally legal to sell?
- Ebola pandemic in 2026?
- Measles cases in U.S. in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve any psychedelic substance for medical use this year?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- Will the FDA approve CagriSema?
Veelgestelde vragen
- Wat zijn de huidige kansen voor What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months??
- Manifold Markets prijst 60-69% op 26% per 8 september 2026.
- Wanneer wordt What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months? afgewikkeld?
- What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months? wordt naar verwachting op 2 september 2027 afgewikkeld.
- Hoe wordt What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months? afgewikkeld?
- Manifold Markets wikkelt deze markt als volgt af: The 12 month phase 3 data indicates 75% vaccine efficacy of R21 in annual malaria sites in children at 12 months after the first dose was delivered.